China NT Pharma Group Company Limited

SEHK:1011 Stock Report

Market Cap: HK$105.6m

China NT Pharma Group Management

Management criteria checks 3/4

China NT Pharma Group's CEO is David Ng, appointed in Jan 1995, has a tenure of 29.75 years. total yearly compensation is CN¥1.67M, comprised of 99% salary and 1% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth HK$10.00K. The average tenure of the management team and the board of directors is 2.9 years and 7.3 years respectively.

Key information

David Ng

Chief executive officer

CN¥1.7m

Total compensation

CEO salary percentage99.0%
CEO tenure29.8yrs
CEO ownership0.009%
Management average tenure2.9yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

Mar 06
A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking

Dec 29
China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking

Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

Oct 30
Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

Is China NT Pharma Group (HKG:1011) Using Too Much Debt?

Apr 13
Is China NT Pharma Group (HKG:1011) Using Too Much Debt?

CEO Compensation Analysis

How has David Ng's remuneration changed compared to China NT Pharma Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥28m

Mar 31 2024n/an/a

-CN¥31m

Dec 31 2023CN¥2mCN¥2m

-CN¥33m

Jun 30 2023n/an/a

-CN¥44m

Mar 31 2023n/an/a

-CN¥55m

Dec 31 2022CN¥2mCN¥2m

-CN¥50m

Sep 30 2022n/an/a

-CN¥121m

Jun 30 2022n/an/a

-CN¥175m

Mar 31 2022n/an/a

-CN¥162m

Dec 31 2021CN¥2mCN¥1m

-CN¥150m

Sep 30 2021n/an/a

-CN¥147m

Jun 30 2021n/an/a

-CN¥145m

Mar 31 2021n/an/a

-CN¥167m

Dec 31 2020CN¥2mCN¥2m

-CN¥189m

Sep 30 2020n/an/a

-CN¥271m

Jun 30 2020n/an/a

-CN¥353m

Mar 31 2020n/an/a

-CN¥351m

Dec 31 2019CN¥6mCN¥6m

-CN¥350m

Sep 30 2019n/an/a

-CN¥547m

Jun 30 2019n/an/a

-CN¥744m

Mar 31 2019n/an/a

-CN¥670m

Dec 31 2018CN¥9mCN¥6m

-CN¥596m

Sep 30 2018n/an/a

-CN¥190m

Jun 30 2018n/an/a

CN¥216m

Mar 31 2018n/an/a

CN¥215m

Dec 31 2017CN¥8mCN¥6m

CN¥214m

Compensation vs Market: David's total compensation ($USD236.76K) is about average for companies of similar size in the Hong Kong market ($USD233.24K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Ng (60 yo)

29.8yrs

Tenure

CN¥1,669,000

Compensation

Mr. Tit Ng, also known as David, has been the Chief Executive Officer and Chairman of China NT Pharma Group Company Limited since 1995. He is a Co-Founder of NT Pharma Group Company Limited. Mr. Ng was app...

Leadership Team

NamePositionTenureCompensationOwnership
Tit Ng
Co-Founder29.8yrsCN¥1.67m0.0095%
CN¥ 10.0k
Jing Fang
Chief Financial Officer4.9yrsno datano data
Ching Mei Ng
Executive Directorless than a yearno datano data
Cheung Cheng
Company Secretaryless than a yearno datano data

2.9yrs

Average Tenure

44yo

Average Age

Experienced Management: 1011's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Tit Ng
Co-Founder29.8yrsCN¥1.67m0.0095%
CN¥ 10.0k
Ching Mei Ng
Executive Directorless than a yearno datano data
Yu Chin
Non-Executive Director14.6yrsCN¥138.00k0.0095%
CN¥ 10.0k
Wei Qian
Non-Executive Director14.6yrsno datano data
Tze Shan Yu
Independent Non-Executive Director7.3yrsCN¥138.00k0.0057%
CN¥ 6.0k
Ming Kwan Ng
Independent Non-Executive Director1.8yrsCN¥138.00kno data
Yubiao Zhao
Independent Non-Executive Director4.8yrsCN¥138.00kno data

7.3yrs

Average Tenure

60yo

Average Age

Experienced Board: 1011's board of directors are considered experienced (7.3 years average tenure).